The triple combination of carflizomib, pomalidomide, and dexamethasone (KPd) is an effective, and well-tolerated option for patients with relapsed and/or refractory multiple myeloma (RRMM), according to a study presented at the 17th International Myeloma Workshop.
In this study, researchers combined data from two single-arm studies and analyzed 183 patients. In both studies, patients were administered KPd in 28-day cycles with treatment continued until disease progression or unacceptable toxicity. The primary outcome was to estimate the overall response rate of KPd (ORR) and secondary endpoints were specified as the assessment of progression-free survival (PFS), overall survival (OS), and safety.
The findings showed that the average number of prior lines of therapy in the pooled population was 4 (range, 1–15), and the ORR for the individual studies was 77% and 70%, respectively with a pooled rate of 73% (95% CI, 67 to 79). The researchers observed that the pooled proportion of patients who had very good partial response or better was 35% (95% CI, 28 to 42), and the average OS was 29.6 months (95% CI, 26 to 34), and 12 and 24-month PFS rates were 49% and 20%, respectively in the population of interest. Overall, the study showed that 78% of patients reported at least one grade 3 or 4 treatment-emergent adverse event (TEAE), with the frequency of grade TEAEs grade 3 or greater in the pooled KPd population consistent with other carflizomib dosing regimens.
“As the need for lenalidomide sparing regimens is increasing, KPd is an important, effective, and well-tolerated option for lenalidomide exposed patients in both early and later relapse settings,” the authors wrote. “Future research should assess these promising results against sound clinical benchmarks.”
Jakubowiak A, et al. Efficacy and Safety of Carflizomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies. Presented at the 17th International Myeloma Workshop; September 12-15, 2019; Boston, MA.